Form 8-K - Current report:
SEC Accession No. 0001564590-21-030018
Filing Date
2021-05-26
Accepted
2021-05-26 16:05:28
Documents
12
Period of Report
2021-05-25
Items
Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant
Item 3.02: Unregistered Sales of Equity Securities

Document Format Files

Seq Description Document Type Size
1 8-K dvax-8k_20210525.htm   iXBRL 8-K 36466
  Complete submission text file 0001564590-21-030018.txt   166895

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA dvax-20210525.xsd EX-101.SCH 5772
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE dvax-20210525_lab.xml EX-101.LAB 19478
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE dvax-20210525_pre.xml EX-101.PRE 11627
5 EXTRACTED XBRL INSTANCE DOCUMENT dvax-8k_20210525_htm.xml XML 3558
Mailing Address 2100 POWELL STREET SUITE 900 EMERYVILLE CA 94608
Business Address 2100 POWELL STREET SUITE 900 EMERYVILLE CA 94608 5108485100
DYNAVAX TECHNOLOGIES CORP (Filer) CIK: 0001029142 (see all company filings)

EIN.: 330728374 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-34207 | Film No.: 21965911
SIC: 2834 Pharmaceutical Preparations